Individuals with generalized anxiety disorder (GAD), a condition characterized by daily excessive worry lasting at least six months, have a high relapse rate even after receiving treatment. Artificial ...

CLEVELAND — Researchers narrowed down what appears to be the correct dosage during a first ever rigorous clinical trial examining LSD as a treatment for generalized anxiety disorder, with results ...

Cognitive behavioral therapy (CBT) should be considered first-line treatment for generalized anxiety disorder in adults, according to a systematic review and network meta-analysis of 66 randomized ...

In the “ThemenCheck Medizin” procedure offered by the German Institute for Quality and Efficiency in Health Care (IQWiG), interested members of the public can submit proposals for the assessment of ...

In early March 2026, Helus Pharma, a Cybin subsidiary, reported positive topline Phase 2 results for HLP004 as an adjunctive intramuscular treatment for adults with moderate-to-severe generalized ...

About The Study: In participants with moderate to severe generalized anxiety disorder, a single dose of MM120 (lysergide D-tartrate) produced a dose-dependent reduction in anxiety. Lysergide, or ...

Helus Pharma HELP shares are down on Thursday following the announcement of topline results from a Phase 2 signal detection study for HLP004, a potential treatment for generalized anxiety disorder ...

On March 5, 2026, Helus Pharma reported topline Phase 2 signal detection results for its investigational NSA HLP004 in adults with moderate-to-severe generalized anxiety disorder who remained ...

Worry is a protective strategy that can keep us stuck. Explore the hidden emotional costs of worry and discover evidence-based ways to break the cycle.

Cybin (HELP) is back in focus after Helus Pharma reported Phase 2 topline data for HLP004 in generalized anxiety disorder, showing clinically meaningful symptom reductions and durable remission in ...